Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 2/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | QPCT | Q16769 | 6/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14482307 | 0.87 | CDK1 (0.38) | SYKBRAFPOLBTDP1 | |
| SCHEMBL12462334 | 0.85 | EGFR (0.43) | SYKEGFRRET | |
| SCHEMBL12462329 | 0.85 | IGF1R (0.39) | SYKEGFRMAPTSMN1; SMN2IGF1R | |
| SCHEMBL14552748 | 0.84 | BRAF (0.40) | SYKEGFRBRAFQPCTMAPT | |
| SCHEMBL2166572 | 0.83 | RET (0.46) | SYKEGFRMAPTRET | |
| SCHEMBL2166734 | 0.83 | MEN1 (0.48) | SYKEGFRIGF1RPOLBRET | |
| SCHEMBL12461998 | 0.83 | SYK (0.38) | SYKEGFRMAPTSMN1; SMN2POLB | |
| SCHEMBL12462325 | 0.82 | ALDH1A1 (0.36) | MAPTSMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL2150669 | 0.82 | NPSR1 (0.36) | EGFRMAPTSMN1; SMN2POLBKMT2A | |
| SCHEMBL14482325 | 0.82 | CTNNB1 (0.40) | EGFRMAPTSMN1; SMN2POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012506-A1 | ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES | NO ZAESUNG (KR) | 2013-01-10 | — | — | US | disclosed |
| US-20130012506-A1 | ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES | NO ZAESUNG (KR) | 2013-01-10 | — | — | US | disclosed |
| US-20130012506-A1 | ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES | NO ZAESUNG (KR) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012506-A1 | ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES | TYMS, TYMP, DCTPP1 | SYK 2095/4885EGFR 4171/4885BRAF 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.